IP Library Granted Patent US 7,674,791
Granted Patent B2
US 7,674,791 · App. 10/552,305 · Granted Mar 9, 2010

Triazolopyrazines and methods of making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,674,791
App. No.
10/552,305
Granted
Mar 9, 2010
Kind
B2
Abstract

The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula I (See formula on paper copy)

Claims (35)

1. A compound of the following formula:

or a pharmaceutically acceptable salt or N-oxide thereof;

wherein

A is aryl or furanyl;

R 2 and R 3 are hydrogen;

X 1 is alkynylene;

X 2 , and X 3 are a bond;

L is a linker of the following formula:

wherein:

R′ is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, oxo, thioxo, cyano, guanadino, amidino, carboxy, sulfo, sulfoxy, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, alkylsulfonylamino, alkoxycarbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfanyl, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylsulfanyl, aryl, aryloxy, arylsulfanyl, aroyl, heteroaryl, heteroaryloxy, heteroarylsulfanyl, or heteroaroyl; provided that two adjacent R′ groups can join together to form a 4- to 8-membered optionally substituted cyclic moiety;

each of p, q, and m, independently, is 0-3;

Y is a bond; and

R 1 is hydrogen.

2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

3. The following compound:

2-Furan-2-yl-6-[1-(2,4,6-trifluoro-benzylamino)-cyclohexylethynyl]-[1,2,4]triazolo[1,5-a]pyrazin-8-ylamine.

4. The following compound:

1-(8-Amino-2-furan-2-yl-[1,2,4]triazolo [1,5-a]pyrazin-6-ylethynyl)-cyclobutanol.

5. The following compound:

1-(8-Amino-2-furan-2-yl- [1,2,4]triazolo [1,5-a]pyrazin-6-ylethynyl)-cyclopentanol.

6. The following compound:

1- [8-Amino-2-(3-fluoro-phenyl)- [1,2,4]triazolo[1,5-a]pyrazin-6-ylethynyl]-cyclopentanol.

7. The following compound:

1-(8-Amino-2-furan-2-yl- [1,2,4]triazolo [1,5-a]pyrazin-6-ylethynyl)-cyclohexanol.

8. The following compound:

2-(8-Amino-2-furan-2-yl- [1 ,2,4]triazolo[1 ,5-a]pyrazin-6-ylethynyl)-indan-2-ol.

9. The following compound:

1-(8-Amino-2-furan-2-yl- [1,2,4]triazolo [1,5-a]pyrazin-6-ylethynyl)-2,2,6-trimethyl-cyclohexanol.

10. The following compound:

6-(3-Cyclohexyl-prop- 1-ynyl)-2-furan-2-yl- [1,2,4]triazolo[1,5-a]pyrazin-8-ylamine.

11. The following compound:

6-(3-Cyclopentyl-prop- 1-ynyl)-2-furan-2-yl- [1,2,4]triazolo[1,5-a]pyrazin-8-ylamine.

12. The following compound:

6-(1-Amino-cyclohexylethynyl)-2-furan-2-yl- [1,2,4]triazolo[1,5-a]pyrazin-8-ylamine.

13. A pharmaceutical composition comprising a compound of anyone of claims 3 - 12 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2009
From: DOWLING, JAMES E.; YAO, GANG; CHANG, HEXI; PENG, HAIRUO; VESSELS, JEFFREY; PETTER, RUSSELL C.; KUMARAVEL, GNANASAMBANDAM
To: BIOGEN IDEC MA INC.
Reel/Frame 023515/0180 →